NeuroDerm Ltd. NDRM announced that it has commenced patient enrollment in a phase II study evaluating the subcutaneously delivered levodopa/carbidopa (LD/CD) solution, ND0612H, for the treatment of patients suffering from advanced Parkinson’s disease. The company’s shares were up 2.3% following the announcement.
The 28-day, multi-center, parallel-group, rater-blinded, randomized pilot study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of two dosing regimens of ND0612H and compare them to the baseline oral standard of care. In the study, a total of 36 advanced Parkinson’s disease patients are expected to be enrolled.
We are encouraged by NeuroDerm’s progress with ND0612H. Per information provided by the company in its press release, ND0612H can prove to be an effective alternative treatment for advanced Parkinson's disease patients who suffer from motor complications that cannot be adequately controlled with currently available treatments and might otherwise require surgical intervention that may be associated with serious adverse effects and death.
Meanwhile, NeuroDerm continues to progress in Europe with a head-to-head PK comparison study on ND0612H and AbbVie Inc.’s ABBV Duodopa. Data from the study should be out in the second quarter of 2016. In addition, the company intends to initiate a pivotal phase III efficacy study on ND0612L for the treatment of patients with moderate-to-severe Parkinson’s disease as well as a long-term safety follow-up in the first half of 2016.
Apart from ND0612H and ND0612L, NeuroDerm is also developing ND0701, a subcutaneously delivered apomorphine formulation for the treatment of patients suffering from severe Parkinson's disease who do not respond well to LD/CD.
We note that several companies including Prothena Corporation plc PRTA are working to bring Parkinson’s disease treatments to the market.
NeuroDerm is a Zacks Rank #2 (Buy) stock. Aerie Pharmaceuticals, Inc. AERI is another favorably ranked stock in the health care sector carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment